We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

In a report released today, Justin Clare from Roth MKM maintained a Buy rating on Altus Power (AMPS – Research Report), with a price target of ...